{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xie Y"],"funding":["National Institute of Environmental Health Sciences","National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS","NIEHS NIH HHS","NCI NIH HHS"],"pagination":["1123-1139"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9035576"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(5)"],"pubmed_abstract":["The oxysterol receptor liver X receptor (LXR) is a nuclear receptor best known for its function in the regulation of lipid and cholesterol metabolism. LXRs, both the α and β isoforms, have been suggested as potential therapeutic targets for several cancer types. However, there was a lack of report on whether and how LXRα plays a role in the development of hepatocellular carcinoma (HCC). In the current study, we found that systemic activation of LXRα in the VP-LXRα knock-in (LXRαKI) mice or hepatocyte-specific activation of LXRα in the VP-LXRα transgenic mice sensitized mice to liver tumorigenesis induced by the combined treatment of diethylnitrosamine (DEN) and 3,3',5,5'-tetrachloro-1,4-bis (pyridyloxy) benzene (TCPOBOP). Mechanistically, the LXRα-responsive up-regulation of interleukin-6 "],"journal":["Hepatology communications"],"pubmed_title":["Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma."],"pmcid":["PMC9035576"],"funding_grant_id":["P30 DK120531","DK117370","P30 CA047904","R35 ES030429","ES030429","R01 DK117370"],"pubmed_authors":["Xie W","Guan J","Xu M","Xie Y","Xu P","Bell A","Ma X","Zhang M","Monga SP","Yang D","Wang J","Lu B","Liu Y","Zhu J","Sun R","Gao L","Lu P","Ren S","Cai X"],"additional_accession":[]},"is_claimable":false,"name":"Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma.","description":"The oxysterol receptor liver X receptor (LXR) is a nuclear receptor best known for its function in the regulation of lipid and cholesterol metabolism. LXRs, both the α and β isoforms, have been suggested as potential therapeutic targets for several cancer types. However, there was a lack of report on whether and how LXRα plays a role in the development of hepatocellular carcinoma (HCC). In the current study, we found that systemic activation of LXRα in the VP-LXRα knock-in (LXRαKI) mice or hepatocyte-specific activation of LXRα in the VP-LXRα transgenic mice sensitized mice to liver tumorigenesis induced by the combined treatment of diethylnitrosamine (DEN) and 3,3',5,5'-tetrachloro-1,4-bis (pyridyloxy) benzene (TCPOBOP). Mechanistically, the LXRα-responsive up-regulation of interleukin-6 ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-07T03:19:52.127Z","creation":"2025-04-04T19:32:17.356Z"},"accession":"S-EPMC9035576","cross_references":{"pubmed":["34981658"],"doi":["10.1002/hep4.1880"]}}